StockData
MDTNYSEElectromedical & Electrotherapeutic ApparatusFiscal year ends April 24

Medtronic plc

Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 3, 2026
$92.77−1.98 (-2.09%)

Close on Oct 19, 2026

Market cap
$119.22B
P/E (TTM)
22.8
Dividend yield
3.06%

About Medtronic

Electromedical & Electrotherapeutic Apparatus, SIC 3845

Medtronic plc is a global healthcare technology enterprise that engineers, manufactures, and markets device-based therapies and medical solutions. The company operates primarily through three core portfolios: Cardiovascular, Neuroscience, and Medical Surgical. Its offerings encompass cardiac pacemakers, defibrillators, ablation catheters, heart valves, and stent grafts, as well as cranial and spinal implants, surgical navigation, robotic guidance systems, neurostimulators, and drug delivery devices. Additionally, it provides advanced surgical tools, electrosurgical instruments, hernia meshes, and patient monitoring and airway management equipment. Medtronic supplies its products to healthcare systems, hospitals, ambulatory surgery centers, physician clinics, and specialized medical professionals across numerous clinical disciplines.

The company conducts commercial activities globally, serving customers in more than 150 countries. Its international manufacturing footprint spans production facilities worldwide, supported by a global workforce exceeding 95,000 full-time employees, with 43% located in the United States and Puerto Rico. Medtronic maintains its corporate headquarters in Galway, Ireland.

Summary of the business section of Medtronic's latest annual report, written by StockData.

Company profile

Company

Legal name
Medtronic plc
Founded
1949
Headquarters
Galway, Ireland
Address
Building Two Parkmore Business Park West H91 4K49
Phone
01135314381700
Employees
95,000, Apr 24, 2026
Industry
Electromedical & Electrotherapeutic Apparatus
Fiscal year ends
April 24
Auditor
PricewaterhouseCoopers LLP, Minneapolis, Minnesota

Stock & identifiers

Ticker
MDT
Exchange
NYSE
Shares outstanding
1.28B, Aug 28, 2026
Public float
$120.10B, Oct 24, 2025
Filer category
Large accelerated filer
Stock splits
2-for-1, Sep 27, 1999; 2-for-1, Sep 15, 1997; 2-for-1, Sep 29, 1995; 2-for-1, Sep 30, 1994; 2-for-1, Aug 30, 1991; 2-for-1, Aug 31, 1989; 2-for-1, Aug 1, 1980
SEC CIK
1613103
CUSIP
G5960L103
ISIN
USG5960L1038
LEI
549300GX3ZBSQWUXY261
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Geoffrey MarthaChairman and CEO, Director327,866
Harry Skip KiilEVP & President Cardiovascular42,186
Denise L. BlomquistChief Accounting Officer16,398
Michael MarinaroEVP, Pres MedSurg and Americas116,336
Kweli ThompsonEVP & President, Neuroscience35,390
Matthew R. WalterSVP, Chief HR Officer39,928
Michelle QuinnEVP, GC and Secretary26,721
Thierry PietonEVP & Chief Financial Officer49,645
Brett A. WallEVP & Pres Neuroscience82,183
Gregory L. SmithEVP Global Ops & Supply Chain51,830
Gary Louis CoronaInterim CFO44,255
Ivan K. FongEVP GENERAL COUNSEL & SECR54,692
Sean SalmonEVP & President Cardiovascular64,722
Jennifer M. KirkChief Accounting Officer28,011
Joon Sup LeeDirector1,803
Craig ArnoldDirector42,185
William R. JellisonDirector6,444
Scott C. DonnellyDirector23,924
Randall J. HoganDirector86,082
Kendall J. PowellDirector54,380
Lidia FonsecaDirector7,644
Kevin E. LoftonDirector10,140
Elizabeth G. NabelDirector19,584
John P. GroetelaarsDirector1,444
Gregory P. LewisDirector5,754

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2026
Geoff Martha
$22.94M$22.45M$7.27M$74$97
FY2025
Geoff Martha
$21.24M$26.09M$5.65M$98$149
FY2025
Martha
$21.24M$26.09M$5.65M$98$149
FY2024
Geoff Martha
$20.08M$11.12M$7.59M$90$135
FY2024
Martha
$20.08M$11.12M$7.59M$90$135
FY2023
Geoff Martha
$15.39M$3.32M$5.39M$99$131

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Employees

Headcount reported in annual reports

“Medtronic has over 95,000 full-time employees, of which 43% are based in the U.S.”

Corporate history

Events identified from SEC filings

DateEventDetails
Oct 15, 2025DelistingNotice of delisting from exchange (Form 25)
Sep 29, 2025ListingRegistration of securities on an exchange (Form 8-A)
Sep 29, 2025DelistingNotice of delisting from exchange (Form 25)
Jul 2, 2025DelistingNotice of delisting from exchange (Form 25)
Jun 3, 2024ListingRegistration of securities on an exchange (Form 8-A)
Mar 15, 2023DelistingNotice of delisting from exchange (Form 25)
Mar 10, 2023DelistingNotice of delisting from exchange (Form 25)
Dec 2, 2022DelistingNotice of delisting from exchange (Form 25)
Sep 21, 2022ListingRegistration of securities on an exchange (Form 8-A)
Mar 8, 2021DelistingNotice of delisting from exchange (Form 25)
Oct 14, 2020DelistingNotice of delisting from exchange (Form 25)
Sep 29, 2020ListingRegistration of securities on an exchange (Form 8-A)
Jul 2, 2019ListingRegistration of securities on an exchange (Form 8-A)
Mar 7, 2019ListingRegistration of securities on an exchange (Form 8-A)
Jul 26, 2016Tender offerThird-party tender offer for the company's shares
Jul 17, 2015MergerRegistration of securities for a merger or exchange offer (S-4)
Mar 25, 2015Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jan 27, 2015Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jan 27, 2015Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jan 15, 2015Name changeName changed from Medtronic Ltd to Medtronic plc
Nov 21, 2014Name changeName changed from Medtronic Holdings Ltd to Medtronic Ltd
Jul 14, 2014MergerRegistration of securities for a merger or exchange offer (S-4)